Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

The Belfast Haemophilia Centre, based at Royal Victoria Hospital (RVI), was designated as a reference centre.

  • Read more about The Belfast Haemophilia Centre, based at Royal Victoria Hospital (RVI), was designated as a reference centre.

In 1979, return records show no cryoprecipitate; a small amount of Elstree Factor 8; 1,078,110 units of Oxford Factor 8; and 906,830 units of commercial (Factorate, Koate, Hemofil).

  • Read more about In 1979, return records show no cryoprecipitate; a small amount of Elstree Factor 8; 1,078,110 units of Oxford Factor 8; and 906,830 units of commercial (Factorate, Koate, Hemofil).

The 1977 annual return from the Oxford Haemophilia Centre recorded no use of cryoprecipitate at all and greater use of commercial concentrates than NHS.

  • Read more about The 1977 annual return from the Oxford Haemophilia Centre recorded no use of cryoprecipitate at all and greater use of commercial concentrates than NHS.

Except for two patients on a period of prophylaxis with commercial concentrate noted below, all 10 other severe haemophiliac participants were treated with NHS freeze-dried factor-VIII concentrate prepared by the Lister Institute Laboratories.

  • Read more about Except for two patients on a period of prophylaxis with commercial concentrate noted below, all 10 other severe haemophiliac participants were treated with NHS freeze-dried factor-VIII concentrate prepared by the Lister Institute Laboratories.

Dr Delamore stated that he appreciated that the freeze-dried preparations were much more suitable for home treatment, which he now hoped to institute in selected cases.

  • Read more about Dr Delamore stated that he appreciated that the freeze-dried preparations were much more suitable for home treatment, which he now hoped to institute in selected cases.

At the Hepatitis Working Party's meeting the position in relation to the occurence of cases of AIDS in haemophilia A patients treated with commercial factor concentrates was reviewed. It was stated that there had been two cases of the syndrome in the UK.

  • Read more about At the Hepatitis Working Party's meeting the position in relation to the occurence of cases of AIDS in haemophilia A patients treated with commercial factor concentrates was reviewed. It was stated that there had been two cases of the syndrome in the UK.

The Council of Europe issued its recommendations which included avoiding, the use of coagulation factor concentrates prepared from large plasma pools and informing people with haemophilia of the potential health hazards of haemotherapy and the possibilities of minimising these risks.

  • Read more about The Council of Europe issued its recommendations which included avoiding, the use of coagulation factor concentrates prepared from large plasma pools and informing people with haemophilia of the potential health hazards of haemotherapy and the possibilities of minimising these risks.

Professor Bloom stated in a letter to the haemophilia centres directors "I hope that it will be possible rapidly to vary the Product Licence for relevant imported products to take account of these recent developments."

  • Read more about Professor Bloom stated in a letter to the haemophilia centres directors "I hope that it will be possible rapidly to vary the Product Licence for relevant imported products to take account of these recent developments."

Dr Walford, wrote a memo to Dr Field regarding Dr Galbraith's conclusion on the withdrawal of all blood products from donated blood in the USA.

  • Read more about Dr Walford, wrote a memo to Dr Field regarding Dr Galbraith's conclusion on the withdrawal of all blood products from donated blood in the USA.

Dr Galbraith (PHLS) concluded in a letter to Dr Ian Field (DHSS) that all products made from blood donated in the USA after 1978 should be withdrawn from use.

  • Read more about Dr Galbraith (PHLS) concluded in a letter to Dr Ian Field (DHSS) that all products made from blood donated in the USA after 1978 should be withdrawn from use.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 45
  • Page 46
  • Page 47
  • Page 48
  • Current page 49
  • Page 50
  • Page 51
  • Page 52
  • Page 53
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.